Hyderabad: Strengthening the city’s position as a leading global capability centre (GCC) for the pharmaceutical sector, Sanofi Healthcare India has announced a major expansion of its Hyderabad facility. The French biopharma major has added approximately 2.7 lakh square feet to its existing campus, taking the total built-up area to around 5 lakh square feet.
The expansion is part of Sanofi’s long-term investment commitment of €400 million by 2030 in its Hyderabad GCC. With this addition, the workforce capacity of the centre is expected to increase to between 4,500 and 5,000 employees, up from the originally projected 2,600. This places the facility among the top three largest pharma GCCs in India.
One of Hyderabad’s Largest Pharma GCCs
The move also makes Sanofi’s GCC the second-largest pharma capability centre in Hyderabad, after Novartis, which employs around 9,000 people in the city. The Sanofi facility, located in HITEC City, has grown steadily since it began operations in 2019.
The Hyderabad hub supports critical functions across Sanofi’s global operations, including drug research and development, manufacturing processes, and lifecycle access. It also houses advanced capabilities in artificial intelligence (AI), digital health, data analytics, medical affairs, and intelligent automation.
Boost to Hyderabad’s Life Sciences Ecosystem
Officials said the expansion reflects Hyderabad’s rising stature as a global hub for innovation-driven life sciences. The centre caters to Sanofi’s global affiliates and supports end-to-end operations across multiple business functions.
State leaders highlighted that such investments align with Telangana’s focus on high-skilled employment, scientific innovation, and digital transformation. The facility is seen as a key contributor to Hyderabad’s evolution from a manufacturing base into a strategic digital and innovation hub for global biopharma companies.
Next Phase of Value Creation
The newly expanded campus is expected to further enhance Hyderabad’s reputation as a destination for global life sciences companies seeking advanced digital and analytics capabilities. Industry observers note that the integration of AI, automation, and enterprise operations within the GCC model represents the next phase of value creation in the pharmaceutical sector.
With continued investments from global players like Sanofi, Hyderabad’s position as one of India’s leading pharma and life sciences clusters continues to strengthen.
